CLAIMS

1- Use of EYP001 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease in a patient suffering of the disease, , wherein the disease is selected from the group consisting of hepatitis B infection and nonalcoholic steatohepatitis (NASH), and wherein EYP001 is to be administered once a day at a dose in the range from 25 to 800 mg per day for at least 3 weeks.

2- The use according to claim 1, wherein the treatment regimen has a period in which EYP001 is to be administered once a day and, when pruritus occurs, the EYP001 administration is to be stopped for 1 to 7 days.

3- The use according to any one of claims 1-2, wherein the disease is hepatitis B infection, especially chronic hepatitis B infection.

4- The use according to claim 3, wherein EYP001 is to be used in combination with pegylated IFN-α2a.

5- The use according to any one of claims 1-2, wherein the disease is nonalcoholic steatohepatitis (NASH).

6- The use according to any one of claims 1-5, wherein EYP001 is to be administered once a day at a dose in the range from 25 to 600 mg per day, from 50 to 600 mg per day, from 100 to 400 mg per day, or 200 to 400 mg per day.

7- The use according to any one of claims 1-6, wherein EYP001 is to be administered during a period of time of at least 5, 6, 7 or 8 weeks or 1, 2, 3, 4, 5 or 6 months, for instance from 5, 6, 7 or 8 weeks to 100 weeks.